Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CG-LR2
- Development stage
- Preclinical
- Lead developer
- Lerna Biopharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
CG-LR2 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Lerna Biopharma (formerly Cargene Therapeutics) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), also known as Non-Alcoholic Steatohepatitis (NASH). The drug is designed to silence a specific, currently undisclosed, target gene involved in the progression of liver disease through the RNA interference (RNAi) pathway. By reducing the expression of this target mRNA, CG-LR2 aims to mitigate liver inflammation and fibrosis, addressing the underlying pathology of MASH. The development of CG-LR2 is part of Lerna Biopharma's broader pipeline of siRNA therapeutics focused on liver and ophthalmic disorders.
Beyond the preview
Go deeper on CG-LR2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CG-LR2.